REGULAR CONTENT
Final ID
469
Type
Original Scientific Research-Oral or Pos
Authors
S Kantharia1, N Cornish2, L Portnow3, J Shah2, I Brichkov2, J Shaw2, L Harris2, S Honig4, S Sobolevsky4
Institutions
1N/A, Brooklyn, NY, 2Maimonides Medical Center, Brooklyn, NY, 3Maimonides Medical Center, Brooklyn, NY, 4N/A, New York, NY
Purpose
To retrospectively evaluate technical efficacy, safety and treatment outcomes of percutaneous radiofrequency ablation (RFA) of lung tumors in patients not amenable to surgery at a community hospital.
Materials & Methods
Eligible tumors were defined as those in patients with poor pulmonary function test results for whom tumor resection would further diminish functionality. 24 patients (15 male, 9 female) with a median age of 72 (n = 29 total tumors) underwent percutaneous CT guided RFA for biopsy proven malignancies between Sept 2010 and June 2016. Response to treatment was assessed by non-contrast CT performed immediately post procedure and approximately 3, 6 and 12 months following RFA. Patient demographics, technical success following single-session RFA, post procedure complications and disease response were assessed and compared with data available in literature.
Results
Technical success, defined as 30% decrease in longest tumor diameter, was achieved in 83.3 % (15 /18) of patients who complied with post procedure imaging protocol. Immediate post procedure complications occurred in 27.6% (8/29) ablations with pneumothorax being the most common, 17.2% (5/29). Mean survival is 28.5 months (95% CI: 19.7-37.3) in 18 patients. Disease recurrence was seen in 12.5% (3/24) patients. No immediate treatment mortality was found.
Conclusions
RFA of lung tumors is a well-tolerated procedure with a low incidence of minor complications and tumor recurrence and a high rate of successful tumor response. When compared to existing literature, we found a lower overall rate of complication. Technical success rate and mean survival time was comparable to published results in the literature. As an urban community center where patients often present at a later disease stage with fewer resources and worse comorbidities, finding technical success rates, positive patient outcomes and complication rates comparable with or better than found in the literature is a positive endorsement of the potential success of tumor RFA programs outside of the academic setting. RFA should be considered a valuable treatment option for patients with medically inoperable lung malignancies.
Final ID
469
Type
Original Scientific Research-Oral or Pos
Authors
S Kantharia1, N Cornish2, L Portnow3, J Shah2, I Brichkov2, J Shaw2, L Harris2, S Honig4, S Sobolevsky4
Institutions
1N/A, Brooklyn, NY, 2Maimonides Medical Center, Brooklyn, NY, 3Maimonides Medical Center, Brooklyn, NY, 4N/A, New York, NY
Purpose
To retrospectively evaluate technical efficacy, safety and treatment outcomes of percutaneous radiofrequency ablation (RFA) of lung tumors in patients not amenable to surgery at a community hospital.
Materials & Methods
Eligible tumors were defined as those in patients with poor pulmonary function test results for whom tumor resection would further diminish functionality. 24 patients (15 male, 9 female) with a median age of 72 (n = 29 total tumors) underwent percutaneous CT guided RFA for biopsy proven malignancies between Sept 2010 and June 2016. Response to treatment was assessed by non-contrast CT performed immediately post procedure and approximately 3, 6 and 12 months following RFA. Patient demographics, technical success following single-session RFA, post procedure complications and disease response were assessed and compared with data available in literature.
Results
Technical success, defined as 30% decrease in longest tumor diameter, was achieved in 83.3 % (15 /18) of patients who complied with post procedure imaging protocol. Immediate post procedure complications occurred in 27.6% (8/29) ablations with pneumothorax being the most common, 17.2% (5/29). Mean survival is 28.5 months (95% CI: 19.7-37.3) in 18 patients. Disease recurrence was seen in 12.5% (3/24) patients. No immediate treatment mortality was found.
Conclusions
RFA of lung tumors is a well-tolerated procedure with a low incidence of minor complications and tumor recurrence and a high rate of successful tumor response. When compared to existing literature, we found a lower overall rate of complication. Technical success rate and mean survival time was comparable to published results in the literature. As an urban community center where patients often present at a later disease stage with fewer resources and worse comorbidities, finding technical success rates, positive patient outcomes and complication rates comparable with or better than found in the literature is a positive endorsement of the potential success of tumor RFA programs outside of the academic setting. RFA should be considered a valuable treatment option for patients with medically inoperable lung malignancies.